Deborah L Dobrzynski

Learn More
Male germ cell tumor (GCT) is a highly curable malignancy, which exhibits exquisite sensitivity to cisplatin treatment. The genetic pathway(s) that determine the chemotherapy sensitivity in GCT remain largely unknown. We studied epigenetic changes in relation to cisplatin response by examining promoter hypermethylation in a cohort of resistant and sensitive(More)
PURPOSE To assess response, overall survival, and relapse-free survival of patients with good-risk metastatic germ cell tumor (GCT) by International Germ Cell Consensus Classification Group (IGCCCG) criteria treated with four cycles of etoposide and cisplatin (EP). PATIENTS AND METHODS Two hundred eighty-nine patients with IGCCCG good-risk GCT were(More)
PURPOSE The prognostic information provided by alpha-fetoprotein and human chorionic gonadotrophin in the management of germ cell tumor (GCT) patients is a biochemical reflection of tumor differentiation. Ki67, p53, and apoptosis have been found to be related to proliferation (Ki67), cell death (p53, apoptosis), and possibly differentiation chemoresistance(More)
4533 Background: Phase 3 trials at MSKCC showed 4 cycles of EP to be effective and tolerable treatment for good risk advanced GCTs (JCO 1997;15:2553). Additional patients (pts) have been treated and follow-up (f/u) updated to detect late relapses. METHODS 379 pts with good risk GCT received EP from 11/82-12/02 on 4 protocols. MSKCC criteria (Cancer(More)
  • 1